AstraZeneca topped second-quarter profit expectations and backed its 2026 forecasts on Monday on demand for its therapies. The company’s core earnings for the three months ended June 30 rose 18% to $2.63 per share, while total revenue jumped 5% to $15.38 billion at constant-currency rates.
Financial Performance
Analysts on average were expecting profit of $2.48 per share on sales of $15.39 billion, according to a company-compiled consensus. AstraZeneca continues to expect 2026 core earnings per share to increase by a low double-digit percentage, with total revenues rising at a mid-to-high-single-digit rate.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
